Loading…
Reported covered position: Senior Advisor and Special Projects Coordinator, Rep Wasserman Shultz
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Protecting Patient Access to Cancer and Complex Therapies Act
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: FARRAGUT PARTNERS LLP
Issues relating to HR 4299 and other heath issues.
Protecting Patient Access to Cancer and Complex Therapies Act
Client: SIEMENS HEALTHINEERS · Firm: FARRAGUT PARTNERS LLP
Issues related to HR6197 and HR4299 (patient access)
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
CARDIAC PET ALLIANCE via FARRAGUT PARTNERS LLP
2026 · third_quarter · Q3
Issues related to cardiac PET scans
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VERASTEM ONCOLOGY via FARRAGUT PARTNERS LLP
2026 · third_quarter · Q3
Source: Senate LDA
| EDWARDS LIFESCIENCES LLC |
| 19 |
| 2022–2026 |
| ELISABETH POTTER MD PLLC | 19 | 2022–2026 |
| GENENTECH | 19 | 2022–2026 |
| GILEAD SCIENCES, INC. | 19 | 2022–2026 |
| HERON THERAPEUTICS, INC. | 19 | 2022–2026 |
| JOHNSON & JOHNSON SERVICES, INC. | 19 | 2022–2026 |
| ONEONCOLOGY INC. | 19 | 2022–2026 |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 17 | 2022–2026 |
| DEXCOM INC | 10 | 2024–2026 |
| NOVAVAX, INC. | 10 | 2022–2024 |
| PHARMACOSMOS THERAPEUTICS INC. | 10 | 2024–2026 |
| CYTOKINETICS INC | 9 | 2024–2026 |
| NANTWORKS | 9 | 2022–2023 |
| CHARTER BROKERAGE | 7 | 2024–2025 |
| BRIDGEBIO | 6 | 2025–2026 |
| BeyondSpring Inc. | 5 | 2023–2024 |
| REPLIMUNE | 5 | 2025–2026 |
| UNIQURE INC. | 5 | 2025–2026 |
| AMAG PHARMACEUTICALS, INC. | 4 | 2022 |
| TAKEDA PHARMACEUTICALS AMERICA INC | 4 | 2026 |
| AGILENT TECHNOLOGIES, INC. | 2 | 2026 |
| AGILIX HEALTH | 2 | 2026 |
| AMERICAN INSTITUTE OF ARCHITECTS | 2 | 2026 |
| CARDIAC PET ALLIANCE | 2 | 2026 |
| PACT COALITION | 2 | 2026 |
| VERASTEM ONCOLOGY | 2 | 2026 |
| CARDIOVASCULAR ASSOCIATES OF AMERICA | 1 | 2026 |
| SIEMENS HEALTHINEERS | 1 | 2026 |
| SILFAB SOLAR | 1 | 2026 |
Protecting Patient Access to Cancer and Complex Therapies Act
Client: GENENTECH · Firm: FARRAGUT PARTNERS LLP
Issues related to legislation relating to the 340B drug discount program. Also, legislation relating to Medicare physician payments, including H.R. 4299. Issues relating to GLOBE/GUARD
Protecting Patient Access to Cancer and Complex Therapies Act
Client: PACT COALITION · Firm: FARRAGUT PARTNERS LLP
Issues related to HR 4299
Protecting Patient Access to Cancer and Complex Therapies Act
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: FARRAGUT PARTNERS LLP
Issues relating to HR 4299, Protecting Patients' Access to Cancer and Complex Therapies Act, and general healthcare
Protecting Patient Access to Cancer and Complex Therapies Act
Client: GENENTECH · Firm: FARRAGUT PARTNERS LLP
Issues related to legislation relating to the 340B drug discount program. Also, legislation relating to Medicare physician payments, including H.R. 4299. Issues relating to GLOBE/GUARD
To amend the National Housing Act to direct the Secretary of Housing and Urban Development to establish a program to insure certain second liens secured against property for the purpose of financing the construction of an accessory dwelling unit, and for other purposes.
Client: LANTHEUS MEDICAL IMAGING, INC. · Firm: FARRAGUT PARTNERS LLP
Issues related to user fee reauthorization. Legislative efforts related to the FIND Act (H.R.4479) (S.2609)
To amend the National Housing Act to direct the Secretary of Housing and Urban Development to establish a program to insure certain second liens secured against property for the purpose of financing the construction of an accessory dwelling unit, and for other purposes.
Client: LANTHEUS MEDICAL IMAGING, INC. · Firm: FARRAGUT PARTNERS LLP
Issues related to user fee reauthorization. Legislative efforts related to the FIND Act (H.R.4479) (S.2609)
To amend the National Housing Act to direct the Secretary of Housing and Urban Development to establish a program to insure certain second liens secured against property for the purpose of financing the construction of an accessory dwelling unit, and for other purposes.
Client: LANTHEUS MEDICAL IMAGING, INC. · Firm: FARRAGUT PARTNERS LLP
Issues related to user fee reauthorization. Legislative efforts related to the FIND Act (H.R.4479) (S.2609)
Issues related to HR6197 and HR4299 (patient access)
To designate the facility of the United States Postal Service located at 2600 Michigan Avenue in Kissimmee, Florida, as the "Robert Guevara Post Office Building".
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: FARRAGUT PARTNERS LLP
Issues relating to HR 7299 and other heath issues.
To designate the facility of the United States Postal Service located at 2600 Michigan Avenue in Kissimmee, Florida, as the "Robert Guevara Post Office Building".
Client: TAKEDA PHARMACEUTICALS AMERICA INC · Firm: FARRAGUT PARTNERS LLP
Issues relating to HR 7299 and other heath issues.
Financial Technology Protection Act of 2025
Client: LANTHEUS MEDICAL IMAGING, INC. · Firm: FARRAGUT PARTNERS LLP
Issues related to user fee reauthorization. Legislative efforts related to the FIND Act (H.R.4479) (S.2609)
Financial Technology Protection Act of 2025
Client: LANTHEUS MEDICAL IMAGING, INC. · Firm: FARRAGUT PARTNERS LLP
Issues related to user fee reauthorization. Legislative efforts related to the FIND Act (H.R.4479) (S.2609)
Financial Technology Protection Act of 2025
Client: LANTHEUS MEDICAL IMAGING, INC. · Firm: FARRAGUT PARTNERS LLP
Issues related to user fee reauthorization. Legislative efforts related to the FIND Act (H.R.4479) (S.2609)
To amend the National Housing Act to direct the Secretary of Housing and Urban Development to establish a program to insure certain second liens secured against property for the purpose of financing the construction of an accessory dwelling unit, and for other purposes.
Client: LANTHEUS MEDICAL IMAGING, INC. · Firm: FARRAGUT PARTNERS LLP
Issues related to user fee reauthorization. Legislative efforts related to the FIND Act (H.R.4479) (S.2609)
To amend the National Housing Act to direct the Secretary of Housing and Urban Development to establish a program to insure certain second liens secured against property for the purpose of financing the construction of an accessory dwelling unit, and for other purposes.
Client: LANTHEUS MEDICAL IMAGING, INC. · Firm: FARRAGUT PARTNERS LLP
Issues related to user fee reauthorization. Legislative efforts related to the FIND Act (H.R.4479) (S.2609)
To amend the National Housing Act to direct the Secretary of Housing and Urban Development to establish a program to insure certain second liens secured against property for the purpose of financing the construction of an accessory dwelling unit, and for other purposes.
Client: LANTHEUS MEDICAL IMAGING, INC. · Firm: FARRAGUT PARTNERS LLP
Issues related to user fee reauthorization. Legislative efforts related to the FIND Act (H.R.4479) (S.2609)
To amend the National Housing Act to direct the Secretary of Housing and Urban Development to establish a program to insure certain second liens secured against property for the purpose of financing the construction of an accessory dwelling unit, and for other purposes.
Client: LANTHEUS MEDICAL IMAGING, INC. · Firm: FARRAGUT PARTNERS LLP
Issues related to user fee reauthorization. Legislative efforts related to the FIND Act (H.R.4479) (S.2609)
To amend the National Housing Act to direct the Secretary of Housing and Urban Development to establish a program to insure certain second liens secured against property for the purpose of financing the construction of an accessory dwelling unit, and for other purposes.
Client: LANTHEUS MEDICAL IMAGING, INC. · Firm: FARRAGUT PARTNERS LLP
Issues related to user fee reauthorization. Legislative efforts related to the FIND Act (H.R.4479) (S.2609)
Financial Technology Protection Act of 2025
Client: LANTHEUS MEDICAL IMAGING, INC. · Firm: FARRAGUT PARTNERS LLP
Issues related to user fee reauthorization. Legislative efforts related to the FIND Act (H.R.4479) (S.2609)
Financial Technology Protection Act of 2025
Client: LANTHEUS MEDICAL IMAGING, INC. · Firm: FARRAGUT PARTNERS LLP
Issues related to user fee reauthorization. Legislative efforts related to the FIND Act (H.R.4479) (S.2609)
Financial Technology Protection Act of 2025
Client: LANTHEUS MEDICAL IMAGING, INC. · Firm: FARRAGUT PARTNERS LLP
Issues related to user fee reauthorization. Legislative efforts related to the FIND Act (H.R.4479) (S.2609)
Financial Technology Protection Act of 2025
Client: LANTHEUS MEDICAL IMAGING, INC. · Firm: FARRAGUT PARTNERS LLP
Issues related to user fee reauthorization. Legislative efforts related to the FIND Act (H.R.4479) (S.2609)
Financial Technology Protection Act of 2025
Client: LANTHEUS MEDICAL IMAGING, INC. · Firm: FARRAGUT PARTNERS LLP
Issues related to user fee reauthorization. Legislative efforts related to the FIND Act (H.R.4479) (S.2609)
Positioning the Election Assistance Commission for the Future Act of 2023
Client: LANTHEUS MEDICAL IMAGING, INC. · Firm: FARRAGUT PARTNERS LLP
Issues related to user fee reauthorization. Legislative efforts related to the FIND Act (H.R.4479) (S.2609)
Positioning the Election Assistance Commission for the Future Act of 2023
Client: LANTHEUS MEDICAL IMAGING, INC. · Firm: FARRAGUT PARTNERS LLP
Issues related to user fee reauthorization. Legislative efforts related to the FIND Act (H.R.4479) (S.2609)
Positioning the Election Assistance Commission for the Future Act of 2023
Client: LANTHEUS MEDICAL IMAGING, INC. · Firm: FARRAGUT PARTNERS LLP
Issues related to user fee reauthorization. Legislative efforts related to the FIND Act (H.R.4479) (S.2609)
Positioning the Election Assistance Commission for the Future Act of 2023
Client: LANTHEUS MEDICAL IMAGING, INC. · Firm: FARRAGUT PARTNERS LLP
Issues related to user fee reauthorization. Legislative efforts related to the FIND Act (H.R.4479) (S.2609)
Small Business Growth Act
Client: LANTHEUS MEDICAL IMAGING, INC. · Firm: FARRAGUT PARTNERS LLP
Issues related to user fee reauthorization. Legislative efforts related to the FIND Act (H.R.4479) (S.2609)
Small Business Growth Act
Client: LANTHEUS MEDICAL IMAGING, INC. · Firm: FARRAGUT PARTNERS LLP
Issues related to user fee reauthorization. Legislative efforts related to the FIND Act (H.R.4479) (S.2609)
Small Business Growth Act
Client: LANTHEUS MEDICAL IMAGING, INC. · Firm: FARRAGUT PARTNERS LLP
Issues related to user fee reauthorization. Legislative efforts related to the FIND Act (H.R.4479) (S.2609)
Small Business Growth Act
Client: LANTHEUS MEDICAL IMAGING, INC. · Firm: FARRAGUT PARTNERS LLP
Issues related to user fee reauthorization. Legislative efforts related to the FIND Act (H.R.4479) (S.2609)
Positioning the Election Assistance Commission for the Future Act of 2023
Client: LANTHEUS MEDICAL IMAGING, INC. · Firm: FARRAGUT PARTNERS LLP
Issues related to user fee reauthorization. Legislative efforts related to the FIND Act (H.R.4479) (S.2609)
Positioning the Election Assistance Commission for the Future Act of 2023
Client: LANTHEUS MEDICAL IMAGING, INC. · Firm: FARRAGUT PARTNERS LLP
Issues related to user fee reauthorization. Legislative efforts related to the FIND Act (H.R.4479) (S.2609)
Positioning the Election Assistance Commission for the Future Act of 2023
Client: LANTHEUS MEDICAL IMAGING, INC. · Firm: FARRAGUT PARTNERS LLP
Issues related to user fee reauthorization. Legislative efforts related to the FIND Act (H.R.4479) (S.2609)
Positioning the Election Assistance Commission for the Future Act of 2023
Client: LANTHEUS MEDICAL IMAGING, INC. · Firm: FARRAGUT PARTNERS LLP
Issues related to user fee reauthorization. Legislative efforts related to the FIND Act (H.R.4479) (S.2609)
Small Business Growth Act
Client: LANTHEUS MEDICAL IMAGING, INC. · Firm: FARRAGUT PARTNERS LLP
Issues related to user fee reauthorization. Legislative efforts related to the FIND Act (H.R.4479) (S.2609)
Small Business Growth Act
Client: LANTHEUS MEDICAL IMAGING, INC. · Firm: FARRAGUT PARTNERS LLP
Issues related to user fee reauthorization. Legislative efforts related to the FIND Act (H.R.4479) (S.2609)
Small Business Growth Act
Client: LANTHEUS MEDICAL IMAGING, INC. · Firm: FARRAGUT PARTNERS LLP
Issues related to user fee reauthorization. Legislative efforts related to the FIND Act (H.R.4479) (S.2609)
Small Business Growth Act
Client: LANTHEUS MEDICAL IMAGING, INC. · Firm: FARRAGUT PARTNERS LLP
Issues related to user fee reauthorization. Legislative efforts related to the FIND Act (H.R.4479) (S.2609)
Issues related to pharmacy benefit managers. HR 3258 TACT Act
Issues related to pharmacy benefit managers. HR 3258 TACT Act
Issues related to pharmacy benefit managers. HR 3258 TACT Act
Issues related to pharmacy benefit managers. HR 3258 TACT Act
Facilitating Innovative Nuclear Diagnostics Act of 2021
Client: LANTHEUS MEDICAL IMAGING, INC. · Firm: FARRAGUT PARTNERS LLP
Issues related to user fee reauthorization. Legislative efforts related to the FIND Act (H.R.4479) (S.2609)
Facilitating Innovative Nuclear Diagnostics Act of 2021
Client: LANTHEUS MEDICAL IMAGING, INC. · Firm: FARRAGUT PARTNERS LLP
Issues related to user fee reauthorization. Legislative efforts related to the FIND Act (H.R.4479) (S.2609)
Facilitating Innovative Nuclear Diagnostics Act of 2021
Client: LANTHEUS MEDICAL IMAGING, INC. · Firm: FARRAGUT PARTNERS LLP
Issues related to user fee reauthorization. Legislative efforts related to the FIND Act (H.R.4479) (S.2609)
Facilitating Innovative Nuclear Diagnostics Act of 2021
Client: LANTHEUS MEDICAL IMAGING, INC. · Firm: FARRAGUT PARTNERS LLP
Issues related to user fee reauthorization. Legislative efforts related to the FIND Act (H.R.4479) (S.2609)
Facilitating Innovative Nuclear Diagnostics Act of 2021
Client: LANTHEUS MEDICAL IMAGING, INC. · Firm: FARRAGUT PARTNERS LLP
Issues related to user fee reauthorization. Legislative efforts related to the FIND Act (H.R.4479) (S.2609)
Facilitating Innovative Nuclear Diagnostics Act of 2021
Client: LANTHEUS MEDICAL IMAGING, INC. · Firm: FARRAGUT PARTNERS LLP
Issues related to user fee reauthorization. Legislative efforts related to the FIND Act (H.R.4479) (S.2609)
Facilitating Innovative Nuclear Diagnostics Act of 2021
Client: LANTHEUS MEDICAL IMAGING, INC. · Firm: FARRAGUT PARTNERS LLP
Issues related to user fee reauthorization. Legislative efforts related to the FIND Act (H.R.4479) (S.2609)
Facilitating Innovative Nuclear Diagnostics Act of 2021
Client: LANTHEUS MEDICAL IMAGING, INC. · Firm: FARRAGUT PARTNERS LLP
Issues related to user fee reauthorization. Legislative efforts related to the FIND Act (H.R.4479) (S.2609)
Issues related to FDA approval of oncology drugs and drug pricing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AGILIX HEALTH via FARRAGUT PARTNERS LLP
2026 · third_quarter · Q3
Agilix issues relating to nutrional and dietary policies, CMS remote therapeutic monitoring codes, public health
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AGILENT TECHNOLOGIES, INC. via FARRAGUT PARTNERS LLP
2026 · third_quarter · Q3
Issues related to healthcare tariffs, supply chain, and taxes
Issues related to healthcare tariffs, supply chain, and taxes
Issues related to healthcare tariffs, supply chain, and taxes
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TAKEDA PHARMACEUTICALS AMERICA INC via FARRAGUT PARTNERS LLP
2026 · third_quarter · Q3
Issues relating to HR 4299 and other heath issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PACT COALITION via FARRAGUT PARTNERS LLP
2026 · third_quarter · Q3
Issues related to HR 4299
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
UNIQURE INC. via FARRAGUT PARTNERS LLP
2026 · third_quarter · Q3
Issues related to FDA review of AMT-130
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BRIDGEBIO via FARRAGUT PARTNERS LLP
2026 · third_quarter · Q3
issues related to drug coverage
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACOSMOS THERAPEUTICS INC. via FARRAGUT PARTNERS LLP
2026 · third_quarter · Q3
General representation and issues related to coverage of treatments for chemotherapy induced iron deficiency anemia and chemotherapy induced Myelosuppression. Safe Step Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CYTOKINETICS INC. via FARRAGUT PARTNERS LLP
2026 · third_quarter · Q3
General healthcare representation. Monitoring relevant healthcare legislative and regulatory activity.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DEXCOM, INC. via FARRAGUT PARTNERS LLP
2026 · third_quarter · Q3
General representation. Legislative and regulatory issues related to policies and payments for continuous glucose monitoring
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORGANIZE ACTION NETWORK via FARRAGUT PARTNERS LLP
2026 · third_quarter · Q3
Issues related to the organ donation system and the organ procurement transplantation network.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
ELISABETH POTTER MD PLLC via FARRAGUT PARTNERS LLP
2026 · third_quarter · 3T
Issues related to coverage policy for Medicare reimbursement of breast reconstruction surgery
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via FARRAGUT PARTNERS LLP
2026 · third_quarter · Q3
General representation. Regulations and legislation relating to PBMs and drug pricing. Issues related to the 340B drug discount program
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LANTHEUS MEDICAL IMAGING, INC. via FARRAGUT PARTNERS LLP
2026 · third_quarter · Q3
Issues related to user fee reauthorization. Legislative efforts related to the FIND Act (H.R.4479) (S.2609)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
U.S. WOMEN'S HEALTH ALLIANCE via FARRAGUT PARTNERS LLP
2026 · third_quarter · Q3
Issues related to OB/GYN healthcare providers. Issues relating to alternative payment models. Issues relating to maternal health
Filing targets: Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, SENATE
SPR THERAPEUTICS via FARRAGUT PARTNERS LLP
2026 · third_quarter · Q3
Issues related to coverage of peripheral nerve stimulation
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)
ONEONCOLOGY LLC via FARRAGUT PARTNERS LLP
2026 · third_quarter · Q3
Issues pertaining to Medicare reimbursement. Issues pertaining to drug shortages, legislation regarding the 340B Drug discount program. Issues pertaining to sequestration; Issues related to pharmacy benefit managers. Drug Pricing legislation. Monitoring CMMI Demonstration Projects. CON regulations. CARES implementation.
Issues related to pharmacy benefit managers.
Issues pertaining to Medicare reimbursement. Issues pertaining to drug shortages, legislation regarding the 340B Drug discount program. Issues pertaining to sequestration; Issues related to pharmacy benefit managers. Drug Pricing legislation. Monitoring CMMI Demonstration Projects. CON regulations. CARES implementation
DAIICHI SANKYO INC via FARRAGUT PARTNERS LLP
2026 · third_quarter · Q3
Issues relating to the coverage of treatments for iron deficiency anemia
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GILEAD SCIENCES INC. via FARRAGUT PARTNERS LLP
2026 · third_quarter · Q3
Issues pertaining to the 340B drug discount program.
Coverage and reimbursement policy for HCV and HIV portfolios. Issues pertaining to the six protected classes. Drug pricing legislation- part D redesign. Issues related to Medicaid drug rebate program. Monitoring CMMI demonstrations
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
EDWARDS LIFESCIENCES, LLC via FARRAGUT PARTNERS LLP
2026 · third_quarter · Q3
Coverage and reimbursement policy for medical devices/THV Medicare coverage of breakthrough therapies Policies promoting medical innovation. Coverage with evidence development.
21st Century Cures 2.0
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HERON THERAPEUTICS, INC. via FARRAGUT PARTNERS LLP
2026 · third_quarter · Q3
Issues related to non-opioid alternatives reimbursement. Coverage decisions related to anti nausea treatments. Federal non-opioid directive legislation
Issues related to non-opioid alternatives reimbursement. Coverage decisions related to anti nausea treatments. Federal non-opioid directive legislation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COMMUNITY ONCOLOGY ALLIANCE via FARRAGUT PARTNERS LLP
2026 · third_quarter · Q3
Legislation regarding the 340B Drug discount program. Issues related to pharmacy benefit managers. Drug Pricing legislation. 21st Century Cures 2.0
Issues related to pharmacy benefit managers. TACT Act
Issues pertaining to Medicare reimbursement. Legislation regarding the 340B Drug discount program. Issues pertaining to sequestration; Issues related to pharmacy benefit managers. Drug Pricing legislation. CMMI demonstration (OCM/OCF)
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GENENTECH via FARRAGUT PARTNERS LLP
2026 · third_quarter · Q3
Issues related to legislation relating to the 340B drug discount program. Also, legislation relating to Medicare physician payments, including H.R. 4299. Issues relating to GLOBE/GUARD
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JOHNSON & JOHNSON SERVICES INC via FARRAGUT PARTNERS LLP
2026 · third_quarter · Q3
Issues related to the 340B drug discount program. Medicare Part B. Biosimilar Legislation. Drug pricing legislation. Issues related to ASP reporting. Issues related to patient safety in attorney advertising. Vaccine coverage issues. Maternal health legislation.
Issues related to the 340B drug discount program. Medicare Part B. Biosimilar Legislation. Drug pricing legislation. Issues related to ASP reporting. Issues related to patient safety in attorney advertising. Vaccine coverage issues. Maternal health legislation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN INSTITUTE OF ARCHITECTS via FARRAGUT PARTNERS LLP
2026 · third_quarter · Q3
Issues related to government contracting architect and engineering fees
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN INSTITUTE OF ARCHITECTS via FARRAGUT PARTNERS LLP
2026 · third_quarter · RR
issues related to government contracting architect and engineering fees
CARDIAC PET ALLIANCE via FARRAGUT PARTNERS LLP
2026 · third_quarter · RR
Issues related to cardiac PET scans
VERASTEM ONCOLOGY via FARRAGUT PARTNERS LLP
2026 · third_quarter · RR
Issues related to FDA approval of oncology drugs and drug pricing
AGILIX HEALTH via FARRAGUT PARTNERS LLP
2026 · third_quarter · RR
Issues relating to nutritional and dietary policies
SILFAB SOLAR via FARRAGUT PARTNERS LLP
2026 · third_quarter · RR
Issues related to Section 232 polysilicon tariffs
AGILENT TECHNOLOGIES, INC. via FARRAGUT PARTNERS LLP
2026 · third_quarter · RR
Issues related to healthcare tariffs, supply chain, and taxes
Issues related to healthcare tariffs, supply chain, and taxes
Issues related to healthcare tariffs, supply chain, and taxes
TAKEDA PHARMACEUTICALS AMERICA INC via FARRAGUT PARTNERS LLP
2026 · second_quarter · Q2
Issues relating to HR 7299 and other heath issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
UNIQURE INC. via FARRAGUT PARTNERS LLP
2026 · second_quarter · Q2
Issues related to FDA review of AMT-130
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REPLIMUNE via FARRAGUT PARTNERS LLP
2026 · first_quarter · 1T
issues related to advanced melanoma cancer treatments
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
BRIDGEBIO via FARRAGUT PARTNERS LLP
2026 · second_quarter · Q2
issues related to drug coverage
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACOSMOS THERAPEUTICS INC. via FARRAGUT PARTNERS LLP
2026 · second_quarter · Q2
General representation and issues related to coverage of treatments for chemotherapy induced iron deficiency anemia and chemotherapy induced Myelosuppression
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CYTOKINETICS INC. via FARRAGUT PARTNERS LLP
2026 · second_quarter · Q2
General healthcare representation. Monitoring relevant healthcare legislative and regulatory activity.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DEXCOM, INC. via FARRAGUT PARTNERS LLP
2026 · second_quarter · Q2
General representation. Legislative and regulatory issues related to policies and payments for continuous glucose monitoring
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORGANIZE ACTION NETWORK via FARRAGUT PARTNERS LLP
2026 · second_quarter · Q2
Issues related to the organ donation system and the organ procurement transplantation network.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
ELISABETH POTTER MD PLLC via FARRAGUT PARTNERS LLP
2026 · second_quarter · Q2
Issues related to coverage policy for Medicare reimbursement of breast reconstruction surgery
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via FARRAGUT PARTNERS LLP
2026 · second_quarter · Q2
General representation. Regulations and legislation relating to PBMs and drug pricing. Issues related to the 340B drug discount program
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LANTHEUS MEDICAL IMAGING, INC. via FARRAGUT PARTNERS LLP
2026 · second_quarter · Q2
Issues related to user fee reauthorization. Legislative efforts related to the FIND Act (H.R.4479) (S.2609)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
U.S. WOMEN'S HEALTH ALLIANCE via FARRAGUT PARTNERS LLP
2026 · second_quarter · Q2
Issues related to OB/GYN healthcare providers. Issues relating to alternative payment models. Issues relating to maternal health
Filing targets: Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, SENATE
SPR THERAPEUTICS via FARRAGUT PARTNERS LLP
2026 · second_quarter · Q2
Issues related to coverage of peripheral nerve stimulation
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)
ONEONCOLOGY LLC via FARRAGUT PARTNERS LLP
2026 · second_quarter · Q2
Issues pertaining to Medicare reimbursement. Issues pertaining to drug shortages, legislation regarding the 340B Drug discount program. Issues pertaining to sequestration; Issues related to pharmacy benefit managers. Drug Pricing legislation. Monitoring CMMI Demonstration Projects. CON regulations. CARES implementation
Issues pertaining to Medicare reimbursement. Issues pertaining to drug shortages, legislation regarding the 340B Drug discount program. Issues pertaining to sequestration; Issues related to pharmacy benefit managers. Drug Pricing legislation. Monitoring CMMI Demonstration Projects. CON regulations. CARES implementation.
DAIICHI SANKYO INC via FARRAGUT PARTNERS LLP
2026 · second_quarter · Q2
Issues relating to the coverage of treatments for iron deficiency anemia
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GILEAD SCIENCES INC. via FARRAGUT PARTNERS LLP
2026 · second_quarter · Q2
Coverage and reimbursement policy for HCV and HIV portfolios. Issues pertaining to the six protected classes. Drug pricing legislation- part D redesign. Issues related to Medicaid drug rebate program. Monitoring CMMI demonstrations
Issues pertaining to the 340B drug discount program.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
EDWARDS LIFESCIENCES, LLC via FARRAGUT PARTNERS LLP
2026 · second_quarter · Q2
Coverage and reimbursement policy for medical devices/THV Medicare coverage of breakthrough therapies Policies promoting medical innovation. Coverage with evidence development.
21st Century Cures 2.0
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HERON THERAPEUTICS, INC. via FARRAGUT PARTNERS LLP
2026 · second_quarter · Q2
Issues related to non-opioid alternatives reimbursement. Coverage decisions related to anti nausea treatments. Federal non-opioid directive legislation
Issues related to non-opioid alternatives reimbursement. Coverage decisions related to anti nausea treatments. Federal non-opioid directive legislation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COMMUNITY ONCOLOGY ALLIANCE via FARRAGUT PARTNERS LLP
2026 · second_quarter · Q2
Issues pertaining to Medicare reimbursement. Legislation regarding the 340B Drug discount program. Issues pertaining to sequestration; Issues related to pharmacy benefit managers. Drug Pricing legislation. CMMI demonstration (OCM/OCF)
Legislation regarding the 340B Drug discount program. Issues related to pharmacy benefit managers. Drug Pricing legislation. 21st Century Cures 2.0
Issues related to pharmacy benefit managers. TACT Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GENENTECH via FARRAGUT PARTNERS LLP
2026 · second_quarter · Q2
Issues related to legislation relating to the 340B drug discount program. Also, legislation relating to Medicare physician payments, including H.R. 4299. Issues relating to GLOBE/GUARD
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JOHNSON & JOHNSON SERVICES INC via FARRAGUT PARTNERS LLP
2026 · second_quarter · Q2
Issues related to the 340B drug discount program. Medicare Part B. Biosimilar Legislation. Drug pricing legislation. Issues related to ASP reporting. Issues related to patient safety in attorney advertising. Vaccine coverage issues. Maternal health legislation.
Issues related to the 340B drug discount program. Medicare Part B. Biosimilar Legislation. Drug pricing legislation. Issues related to ASP reporting. Issues related to patient safety in attorney advertising. Vaccine coverage issues. Maternal health legislation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TAKEDA PHARMACEUTICALS AMERICA INC via FARRAGUT PARTNERS LLP
2026 · first_quarter · Q1
Issues relating to HR 7299 and other heath issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TAKEDA PHARMACEUTICALS AMERICA INC via FARRAGUT PARTNERS LLP
2026 · first_quarter · RR
Issues relating to HR 4299, Protecting Patients' Access to Cancer and Complex Therapies Act, and general healthcare
SIEMENS HEALTHINEERS via FARRAGUT PARTNERS LLP
2026 · second_quarter · RR
Issues related to HR6197 and HR4299 (patient access)
CARDIOVASCULAR ASSOCIATES OF AMERICA via FARRAGUT PARTNERS LLP
2026 · second_quarter · RR
Issues related to cardiac PET scans
PACT COALITION via FARRAGUT PARTNERS LLP
2026 · second_quarter · RR
Issues related to patient access
UNIQURE INC. via FARRAGUT PARTNERS LLP
2026 · first_quarter · Q1
Issues related to FDA review of AMT-130
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REPLIMUNE via FARRAGUT PARTNERS LLP
2026 · first_quarter · Q1
issues related to advanced melanoma cancer treatments
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
BRIDGEBIO via FARRAGUT PARTNERS LLP
2026 · first_quarter · Q1
issues related to drug coverage
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACOSMOS THERAPEUTICS INC. via FARRAGUT PARTNERS LLP
2026 · first_quarter · Q1
General representation and issues related to coverage of treatments for chemotherapy induced iron deficiency anemia and chemotherapy induced Myelosuppression
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CYTOKINETICS INC. via FARRAGUT PARTNERS LLP
2026 · first_quarter · Q1
General healthcare representation. Monitoring relevant healthcare legislative and regulatory activity.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DEXCOM, INC. via FARRAGUT PARTNERS LLP
2026 · first_quarter · Q1
General representation. Legislative and regulatory issues related to policies and payments for continuous glucose monitoring
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORGANIZE ACTION NETWORK via FARRAGUT PARTNERS LLP
2026 · first_quarter · Q1
Issues related to the organ donation system and the organ procurement transplantation network.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELISABETH POTTER MD PLLC via FARRAGUT PARTNERS LLP
2026 · first_quarter · Q1
Issues related to coverage policy for Medicare reimbursement of breast reconstruction surgery
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via FARRAGUT PARTNERS LLP
2026 · first_quarter · Q1
General representation. Regulations and legislation relating to PBMs and drug pricing. Issues related to the 340B drug discount program
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LANTHEUS MEDICAL IMAGING, INC. via FARRAGUT PARTNERS LLP
2026 · first_quarter · Q1
Issues related to user fee reauthorization. Legislative efforts related to the FIND Act (H.R.4479) (S.2609)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
U.S. WOMEN'S HEALTH ALLIANCE via FARRAGUT PARTNERS LLP
2026 · first_quarter · Q1
Issues related to OB/GYN healthcare providers. Issues relating to alternative payment models. Issues relating to maternal health
Filing targets: Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, SENATE
SPR THERAPEUTICS via FARRAGUT PARTNERS LLP
2026 · first_quarter · Q1
Issues related to coverage of peripheral nerve stimulation
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)
ONEONCOLOGY LLC via FARRAGUT PARTNERS LLP
2026 · first_quarter · Q1
Issues pertaining to Medicare reimbursement. Issues pertaining to drug shortages, legislation regarding the 340B Drug discount program. Issues pertaining to sequestration; Issues related to pharmacy benefit managers. Drug Pricing legislation. Monitoring CMMI Demonstration Projects. CON regulations. CARES implementation
Issues pertaining to Medicare reimbursement. Issues pertaining to drug shortages, legislation regarding the 340B Drug discount program. Issues pertaining to sequestration; Issues related to pharmacy benefit managers. Drug Pricing legislation. Monitoring CMMI Demonstration Projects. CON regulations. CARES implementation.
DAIICHI SANKYO INC via FARRAGUT PARTNERS LLP
2026 · first_quarter · Q1
Issues relating to the coverage of treatments for iron deficiency anemia
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GILEAD SCIENCES INC. via FARRAGUT PARTNERS LLP
2026 · first_quarter · Q1
Issues pertaining to the 340B drug discount program.
Coverage and reimbursement policy for HCV and HIV portfolios. Issues pertaining to the six protected classes. Drug pricing legislation- part D redesign. Issues related to Medicaid drug rebate program. Monitoring CMMI demonstrations
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EDWARDS LIFESCIENCES, LLC via FARRAGUT PARTNERS LLP
2026 · first_quarter · Q1
21st Century Cures 2.0
Coverage and reimbursement policy for medical devices/THV Medicare coverage of breakthrough therapies Policies promoting medical innovation. Coverage with evidence development.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HERON THERAPEUTICS, INC. via FARRAGUT PARTNERS LLP
2026 · first_quarter · Q1
Issues related to non-opioid alternatives reimbursement. Coverage decisions related to anti nausea treatments. Federal non-opioid directive legislation
Issues related to non-opioid alternatives reimbursement. Coverage decisions related to anti nausea treatments. Federal non-opioid directive legislation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COMMUNITY ONCOLOGY ALLIANCE via FARRAGUT PARTNERS LLP
2026 · first_quarter · Q1
Legislation regarding the 340B Drug discount program. Issues related to pharmacy benefit managers. Drug Pricing legislation. 21st Century Cures 2.0
Issues pertaining to Medicare reimbursement. Legislation regarding the 340B Drug discount program. Issues pertaining to sequestration; Issues related to pharmacy benefit managers. Drug Pricing legislation. CMMI demonstration (OCM/OCF)
Issues related to pharmacy benefit managers. TACT Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GENENTECH via FARRAGUT PARTNERS LLP
2026 · first_quarter · Q1
Issues related to the 340B Drug discount program. Drug Pricing Proposals. Issues related to drug pricing. 21st century cures 2.0 legislation.
Issues regarding Medicare payment policies for Part B drugs. Issues related to the 340B Drug discount program. Drug Pricing Proposals. CMMI Guardrails. Issues related to drug pricing (IPI, Part B reforms). 21st century cures 2.0 legislation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JOHNSON & JOHNSON SERVICES INC via FARRAGUT PARTNERS LLP
2026 · first_quarter · Q1
Issues related to the 340B drug discount program. Medicare Part B. Biosimilar Legislation. Drug pricing legislation. Issues related to ASP reporting. Issues related to patient safety in attorney advertising. Vaccine coverage issues. Maternal health legislation.
Issues related to the 340B drug discount program. Medicare Part B. Biosimilar Legislation. Drug pricing legislation. Issues related to ASP reporting. Issues related to patient safety in attorney advertising. Vaccine coverage issues. Maternal health legislation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
UNIQURE INC. via FARRAGUT PARTNERS LLP
2025 · fourth_quarter · Q4
Issues related to FDA review of AMT-130
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REPLIMUNE via FARRAGUT PARTNERS LLP
2025 · fourth_quarter · Q4
issues related to advanced melanoma cancer treatments
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
BRIDGEBIO via FARRAGUT PARTNERS LLP
2025 · fourth_quarter · Q4
issues related to drug coverage
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACOSMOS THERAPEUTICS INC. via FARRAGUT PARTNERS LLP
2025 · fourth_quarter · Q4
General representation and issues related to coverage of treatments for chemotherapy induced iron deficiency anemia and chemotherapy induced Myelosuppression
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CYTOKINETICS INC. via FARRAGUT PARTNERS LLP
2025 · fourth_quarter · Q4
General healthcare representation. Monitoring relevant healthcare legislative and regulatory activity.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DEXCOM, INC. via FARRAGUT PARTNERS LLP
2025 · fourth_quarter · Q4
General representation. Legislative and regulatory issues related to policies and payments for continuous glucose monitoring
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORGANIZE ACTION NETWORK via FARRAGUT PARTNERS LLP
2025 · fourth_quarter · Q4
Issues related to the organ donation system and the organ procurement transplantation network.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELISABETH POTTER MD PLLC via FARRAGUT PARTNERS LLP
2025 · fourth_quarter · Q4
Issues related to coverage policy for Medicare reimbursement of breast reconstruction surgery
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via FARRAGUT PARTNERS LLP
2025 · fourth_quarter · Q4
General representation. Regulations and legislation relating to PBMs and drug pricing. Issues related to the 340B drug discount program
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LANTHEUS MEDICAL IMAGING, INC. via FARRAGUT PARTNERS LLP
2025 · fourth_quarter · Q4
Issues related to user fee reauthorization. Legislative efforts related to the FIND Act (H.R.4479) (S.2609)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
U.S. WOMEN'S HEALTH ALLIANCE via FARRAGUT PARTNERS LLP
2025 · fourth_quarter · Q4
Issues related to OB/GYN healthcare providers. Issues relating to alternative payment models. Issues relating to maternal health
Filing targets: Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, SENATE
SPR THERAPEUTICS via FARRAGUT PARTNERS LLP
2025 · fourth_quarter · Q4
Issues related to coverage of peripheral nerve stimulation
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)
ONEONCOLOGY LLC via FARRAGUT PARTNERS LLP
2025 · fourth_quarter · Q4
Issues related to pharmacy benefit managers.
Issues pertaining to Medicare reimbursement. Issues pertaining to drug shortages, legislation regarding the 340B Drug discount program. Issues pertaining to sequestration; Issues related to pharmacy benefit managers. Drug Pricing legislation. Monitoring CMMI Demonstration Projects. CON regulations. CARES implementation.
Issues pertaining to Medicare reimbursement. Issues pertaining to drug shortages, legislation regarding the 340B Drug discount program. Issues pertaining to sequestration; Issues related to pharmacy benefit managers. Drug Pricing legislation. Monitoring CMMI Demonstration Projects. CON regulations. CARES implementation
DAIICHI SANKYO INC via FARRAGUT PARTNERS LLP
2025 · fourth_quarter · Q4
Issues relating to the coverage of treatments for iron deficiency anemia
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GILEAD SCIENCES INC. via FARRAGUT PARTNERS LLP
2025 · fourth_quarter · Q4
Coverage and reimbursement policy for HCV and HIV portfolios. Issues pertaining to the six protected classes. Drug pricing legislation- part D redesign. Issues related to Medicaid drug rebate program. Monitoring CMMI demonstrations
Issues pertaining to the 340B drug discount program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EDWARDS LIFESCIENCES, LLC via FARRAGUT PARTNERS LLP
2025 · fourth_quarter · Q4
Coverage and reimbursement policy for medical devices/THV Medicare coverage of breakthrough therapies Policies promoting medical innovation. Coverage with evidence development.
21st Century Cures 2.0
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HERON THERAPEUTICS, INC. via FARRAGUT PARTNERS LLP
2025 · fourth_quarter · Q4
Issues related to non-opioid alternatives reimbursement. Coverage decisions related to anti nausea treatments. Federal non-opioid directive legislation
Issues related to non-opioid alternatives reimbursement. Coverage decisions related to anti nausea treatments. Federal non-opioid directive legislation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COMMUNITY ONCOLOGY ALLIANCE via FARRAGUT PARTNERS LLP
2025 · fourth_quarter · Q4
Issues pertaining to Medicare reimbursement. Legislation regarding the 340B Drug discount program. Issues pertaining to sequestration; Issues related to pharmacy benefit managers. Drug Pricing legislation. CMMI demonstration (OCM/OCF)
Issues related to pharmacy benefit managers. TACT Act
Legislation regarding the 340B Drug discount program. Issues related to pharmacy benefit managers. Drug Pricing legislation. 21st Century Cures 2.0
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GENENTECH via FARRAGUT PARTNERS LLP
2025 · fourth_quarter · Q4
Issues regarding Medicare payment policies for Part B drugs. Issues related to the 340B Drug discount program. Drug Pricing Proposals. CMMI Guardrails. Issues related to drug pricing (IPI, Part B reforms). 21st century cures 2.0 legislation.
Issues related to the 340B Drug discount program. Drug Pricing Proposals. Issues related to drug pricing. 21st century cures 2.0 legislation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JOHNSON & JOHNSON SERVICES INC via FARRAGUT PARTNERS LLP
2025 · fourth_quarter · Q4
Issues related to the 340B drug discount program. Medicare Part B. Biosimilar Legislation. Drug pricing legislation. Issues related to ASP reporting. Issues related to patient safety in attorney advertising. Vaccine coverage issues. Maternal health legislation.
Issues related to the 340B drug discount program. Medicare Part B. Biosimilar Legislation. Drug pricing legislation. Issues related to ASP reporting. Issues related to patient safety in attorney advertising. Vaccine coverage issues. Maternal health legislation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
UNIQURE INC. via FARRAGUT PARTNERS LLP
2025 · fourth_quarter · RR
Issues related to FDA review of AMT-130
REPLIMUNE via FARRAGUT PARTNERS LLP
2025 · third_quarter · Q3
issues related to advanced melanoma cancer treatments
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to pharmacy benefit managers.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to pharmacy benefit managers.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE